Cite
HARVARD Citation
Koeditz, D. et al. (2022). Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany. Multiple sclerosis journal, experimental, translational and clinical. 8 (1), p. . [Online].